1
|
Ollivier L, Laprie A, Jouglar E, Claude L, Martin V, Muracciole X, Padovani L, Supiot S, Escande A. [Characteristics of radiotherapy for adolescents and young adults]. Cancer Radiother 2023; 27:736-745. [PMID: 38652674 DOI: 10.1016/j.canrad.2023.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 08/02/2023] [Indexed: 04/25/2024]
Abstract
Radiotherapy for adolescents and young adults is complex in several aspects. The population is very heterogeneous and has characteristics derived from both paediatric and adult populations both in terms of pathology (anatomical pathology, response to treatment) and the patient's physical, biological and psychological characteristics. This article reviews the characteristics to be taken into account in adolescent and young adult patients radiotherapy and more particularly in some of the most common diseases.
Collapse
Affiliation(s)
- L Ollivier
- Département de radiothérapie, institut de cancérologie de l'Ouest (ICO), Saint-Herblain, France
| | - A Laprie
- Département d'oncologie-radiothérapie, oncopole institut Claudius-Regaud, institut universitaire du cancer de Toulouse, université Toulouse III, Toulouse, France
| | - E Jouglar
- Département de radiothérapie, institut Curie, université Paris Science et Lettres, Paris, France
| | - L Claude
- Département de radiothérapie, centre Léon-Bérard, Lyon, France
| | - V Martin
- Département d'oncologie-radiothérapie, Gustave-Roussy, Villejuif, France
| | - X Muracciole
- Département d'oncologie-radiothérapie, Assistance publique-hôpitaux de Marseille, CHU La Timone, CHU Nord, Marseille, France
| | - L Padovani
- Département d'oncologie-radiothérapie, Assistance publique-hôpitaux de Marseille, CHU La Timone, CHU Nord, Marseille, France
| | - S Supiot
- Département de radiothérapie, institut de cancérologie de l'Ouest (ICO), Saint-Herblain, France
| | - A Escande
- Département de radiothérapie, centre Léonard-de-Vinci, Dechy, France; Laboratoire CRIStAL, UMR 9186, université de Lille, Villeneuve-d'Ascq, France.
| |
Collapse
|
2
|
Gueiderikh A, Ung M, Lazarovici J, Danu A, Ghez D, Saleh K, Dragani M, Noël N, Bigenwald C, Willekens C, Ribrag V, Michot JM, Martin V. Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases. Cancer Radiother 2023; 27:370-375. [PMID: 37156711 DOI: 10.1016/j.canrad.2023.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 03/30/2023] [Accepted: 04/15/2023] [Indexed: 05/10/2023]
Abstract
PURPOSE Follicular lymphoma (FL) is one of the most common lymphoma. Occasionally, FL is associated with tumoral epidural compression and management of these patients remain poorly codified. This study aims to report incidence, clinical characteristics, management and outcomes of patients with FL and tumoral epidural compression. MATERIAL AND METHODS Observational, retrospective cohort study of adult patients with FL and epidural tumor compression, treated in a French Institute over the last 20 years (2000-2021). RESULTS Between 2000 and 2021, 1382 patients with FL were followed by the haematological department. Of them, 22 (1.6%) patients (16 men and 6 women) had follicular lymphoma with epidural tumor compression. At epidural tumor compression occurrence, 8/22 (36%) patients had a neurological clinical deficit (motor, sensory or sphincter function) and 14/22 (64%) had tumor pain. All patients were treated with immuno-chemotherapy; the main regimen being used was R-CHOP plus high dose IV methotrexate in 16/22 (73%) patients. Radiotherapy for tumor epidural compression was performed in 19/22 (86%) patients. With a median follow-up of 60 months (range=[1-216]), 5 year local tumor relapse free survival was achieved in 65% (95% CI 47-90%) of patients. The median PFS was of 36 months (95% CI 24-NA) and 5 years OS estimate was 79% (95% CI 62-100%). Two patients developed a relapse at a second epidural site. CONCLUSION FL with tumoral epidural compression reached 1.6% of all FL patients. Management based on immuno-chemotherapy with radiotherapy appeared to produce comparable outcomes with the general FL population.
Collapse
Affiliation(s)
- A Gueiderikh
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
| | - M Ung
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J Lazarovici
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - A Danu
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - D Ghez
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - K Saleh
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - M Dragani
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - N Noël
- Internal medicine department, hôpital Bicêtre, AP-HP, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - C Bigenwald
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - C Willekens
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - V Ribrag
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J-M Michot
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - V Martin
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| |
Collapse
|
3
|
Magnoli F, Marchiori D, Facchi S, Martin V, Campiotti L, Merli M, Sessa F, Tibiletti MG, Uccella S. High frequency of BCL2 gene rearrangement-negative follicular lymphoma in northwestern Italy. Cancer Genet 2023; 274-275:1-9. [PMID: 36917896 DOI: 10.1016/j.cancergen.2023.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 02/10/2023] [Accepted: 03/02/2023] [Indexed: 03/08/2023]
Abstract
BCL2 rearrangement is reported to be an early pathogenetic event in follicular lymphoma (FL) and it is considered as a reliable marker in the follow up of the disease. We aimed to investigate the frequency of BCL2 rearrangement in FLs from northwestern Italy, to evaluate their clinicopathological features, and to investigate alternative genetic aberrations in BCL2-negative FLs. We collected a series of 76 consecutive FLs diagnosed between 2013 and 2016. All lymphomas underwent histopathological review. Interphasic fluorescent in situ hybridization (FISH) was performed with break apart probes targeting BCL2, IGH, BCL6 and MYC on paraffin embedded (PE) and fresh frozen (FF) specimens. 1p36 region and p53 locus in BLC2-negative cases were investigated using dual color probes. Karyotype analysis was available in a subset of cases. BCL2 rearrangements were detected in 39 cases (51,3%). Of the remaining 37, 6 showed IGH rearrangement, and were further tested: 1 showed variant BCL2 translocation, 1 had BCL6 rearrangement, and the other 4 were negative for further gene rearrangements. FISH on FF specimens detected small BCL2+ clones in cases otherwise categorized as BCL2-. 1p36 and p53 deletion were observed in 1 and 8 BCL2- FLs, respectively. Karyotype analysis documented 3q, 1p and BCL6 alternative abnormalities in 3 cases. In conclusion, BCL2 rearrangement is not a constant finding in FL, its frequency being probably affected by geographical factors. Thus, it should not be considered as a reliable molecular marker in the follow up of the disease, unless it is found to be present at the initial diagnosis of FL. Alternative genetic aberrations exist in BCL2-negative cases.
Collapse
Affiliation(s)
| | - Deborah Marchiori
- Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy
| | - Sofia Facchi
- Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy
| | - Vittoria Martin
- Institute of Pathology, Ente Ospedaliero Cantonale (EOC), Locarno, Switzerland
| | - Leonardo Campiotti
- Unit of Internal Medicine, Department of Medicine and Surgery, Università degli Studi dell'Insubria, Varese, Italy
| | - Michele Merli
- Unit of Hematology, ASST dei Sette Laghi, Varese, Italy
| | - Fausto Sessa
- Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy
| | | | - Silvia Uccella
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanule, Milan, Italy; Pathology Service, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, Milan 20089, Italy.
| |
Collapse
|
4
|
Abstract
A third of children with cancer receive radiotherapy as part of their initial treatment, which represents 800 paediatric irradiations per year in France carried out in 15 specialized centres approved on the recommendations of the French national cancer institute in decreasing order of frequency, the types of cancer that require irradiation are: brain tumours, neuroblastomas, Ewing's sarcomas, Hodgkin's lymphomas, soft tissue sarcomas including rhabdomyosarcomas, and nephroblastomas. The treatment guidelines follow the recommendations of the French society for childhood cancers (SFCE) or the French and European prospective protocols. The therapeutic indications, the technical and/and ballistic choices of complex cases are frequently discussed during bimonthly paediatric radiotherapy technical web-conferences. All cancers combined, overall survival being 80%, long-term toxicity logically becomes an important concern, making the preparation of treatments complex. The irradiation methods include all the techniques currently available: 3D conformational irradiation, intensity modulation radiation therapy, irradiation under normal or hypofractionated stereotaxic conditions, brachytherapy and proton therapy. We present the update of the recommendations of the French society for radiation oncology on the indications, the technical methods of realization and the organisation and the specificities of paediatric radiation oncology.
Collapse
Affiliation(s)
- A Laprie
- Département d'oncologie radiothérapie, Institut universitaire du cancer de Toulouse-Oncopole (IUCT-oncopole), université Paul-Sabatier Toulouse III, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.
| | - V Bernier
- Département d'oncologie radiothérapie, Institut de cancérologie de Lorraine centre Alexis-Vautrin, 6, avenue de Bourgogne, CS 30519, 54519 Vandœuvre-lès-Nancy cedex, France
| | - L Padovani
- Département de cancérologie radiothérapie, CHU, 13000 Marseille, France; Université Aix-Marseille, 13000 Marseille, France
| | - V Martin
- Département de cancérologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - C Chargari
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Service de santé des armées, 75000 Paris, France
| | - S Supiot
- Département de radiothérapie, Institut de cancérologie de l'Ouest (ICO) centre René-Gauducheau, 44800 Saint-Herblain, France; Université de Nantes, 44000 Nantes, France
| | - L Claude
- Département d'oncologie radiothérapie, centre Léon-Bérard, 28, rue Laennec, 69373 Lyon cedex 08, France
| |
Collapse
|
5
|
Abstract
Abstract
Study question
Could the urine estrone–3-glucuronide (E3G) assay be used efficiently to monitor a controlled ovarian hyperstimulation (COH) cycle, in comparison to a serum estradiol (E2) assay?
Summary answer
E3G testing provides an alternative to serum E2 assessment and a new “patient friendly” approach for COH monitoring.
What is known already
In many IVF clinics basic monitoring tools for controlled ovarian stimulation during IVF procedure are ultrasound measurements of follicle growth and hormone assessment of serum E2 levels. The monitoring can occur 4–6 times during stimulation, but repeated blood sampling causes patient stress. In contrast, E3G sampling, one of principal metabolites of estradiol in urine, is non-invasive and can be performed by the patients themselves and measured by fluorescent immunoassay. A correlation has been shown between concentrations of E2 present in plasma and concentrations of E3G in different phases of menstruation cycle.
Study design, size, duration
This is a pilot, prospective study, in a single IVF clinic. Twenty female participants were recruited November 2020 -January 2021, aged 25–43 years and BMI: 18–28kg/m2. Dynamic change of serum E2 and urine E3G at ovarian stimulation monitoring are being analyzed.
Participants/materials, setting, methods
Concurrent urine E3G and serum E2 values were collected from patients who provided between 2 and 4 samples on different days of their COH IVF cycle. Serum E2 values were assessed routinely, while E3G values were measured and validated using a fluorescent immunoassay Mira Fertility Plus® analyzer.Main results and the role of chance: The urine E3G of assay was validated for intra- and inter-assay variability with a coefficient of variation of < 20%. It was also validated for analytical and functional sensitivity and sample stability. Linear regression of serum E2 and E3G values of 56 early morning urine samples who had evaluated between Days 4 and 13 of menstruation cycle provided an R = 0,81. Urine E3G values also correlated to follicle growth. Patient survey results showed that urine sampling was the preferred method of analysis.
Limitations, reasons for caution
We have provided proof of principle that urine E3G measurement can be accurately carried out using fluorescent immunoassay technology during routine COH for IVF cycles. The patients’ study group has to be expanded in order to enable us to find the appropriate place of urine E3G assay in COH protocol.
Wider implications of the findings: Urine E3G testing correlates well to serum E2 assessment in COH. Urine E3G assay provides an alternative to serum-based assessment. The ease of urine sampling allows a reduction in patient discomfort during venopuncture, costs, time, and infection risks in epidemics/pandemics, like COViD–19, and offers a patient-friendly approach to ovarian stimulation.
Trial registration number
NA
Collapse
Affiliation(s)
- I Vladimirov
- SBALAGRM-SOFIA, IVF unit, Sofia, Bulgaria
- Sofia University “St. Kliment Ohridski”- Sofia- Bulgaria, Faculty of Biology, Sofia, Bulgaria
| | - V Martin
- SBALAGRM-SOFIA, IVF unit, Sofia, Bulgaria
| | - T Desislava
- SBALAGRM-SOFIA, IVF unit, Sofia, Bulgaria
- Sofia University “St. Kliment Ohridski”- Sofia- Bulgaria, Faculty of Biology, Sofia, Bulgaria
| |
Collapse
|
6
|
Engstrand J, Abreu de Carvalho LF, Aghayan D, Balakrishnan A, Belli A, Björnsson B, Dasari BVM, Detry O, Di Martino M, Edwin B, Erdmann J, Fristedt R, Fusai G, Gimenez-Maurel T, Hemmingsson O, Hidalgo Salinas C, Isaksson B, Ivanecz A, Izzo F, Knoefel WT, Kron P, Lehwald-Tywuschik N, Lesurtel M, Lodge JPA, Machairas N, Marino MV, Martin V, Paterson A, Rystedt J, Sandström P, Serrablo A, Siriwardena AK, Taflin H, van Gulik TM, Yaqub S, Özden I, Ramia JM, Sturesson C. Liver resection and ablation for squamous cell carcinoma liver metastases. BJS Open 2021; 5:6356812. [PMID: 34426830 PMCID: PMC8382975 DOI: 10.1093/bjsopen/zrab060] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 05/17/2021] [Indexed: 12/30/2022] Open
Abstract
Background Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS). Method Members of the European–African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS. Results Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30). Conclusion Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.
Collapse
Affiliation(s)
- J Engstrand
- Division of Surgery, Department of Clinical Sciences, Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden
| | - L F Abreu de Carvalho
- Department of Hepatopancreatobiliary Surgery and Liver Transplantation, Ghent University Hospital, Ghent, Belgium
| | - D Aghayan
- The Intervention Centre, Oslo University Hospital, Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.,Department of Surgery N1, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
| | - A Balakrishnan
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - A Belli
- Department of Abdominal Oncology, HPB Surgical Oncology Unit, National Cancer Institute, Fondazione G. Pascale-IRCCS, Naples, Italy
| | - B Björnsson
- Department of Surgery in Linköping, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
| | - B V M Dasari
- Department of Hepatobiliary and Pancreatic Surgery, Queen Elizabeth Hospital, Birmingham, UK
| | - O Detry
- Department of Abdominal Surgery and Transplantation, CHU Liège, Liège, Belgium
| | - M Di Martino
- HPB Unit, Department of General and Digestive Surgery, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - B Edwin
- The Intervention Centre, Oslo University Hospital, Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway
| | - J Erdmann
- Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands
| | - R Fristedt
- Department of Surgery, Skåne University Hospital, Lund University, Lund, Sweden
| | - G Fusai
- Department of HPB and Liver Transplant Surgery, Royal Free Hospital, NHS Foundation Trust, London, UK
| | - T Gimenez-Maurel
- Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
| | - O Hemmingsson
- Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - C Hidalgo Salinas
- Department of HPB and Liver Transplant Surgery, Royal Free Hospital, NHS Foundation Trust, London, UK
| | - B Isaksson
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - A Ivanecz
- Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia
| | - F Izzo
- Department of Abdominal Oncology, HPB Surgical Oncology Unit, National Cancer Institute, Fondazione G. Pascale-IRCCS, Naples, Italy
| | - W T Knoefel
- Department of Surgery (A), Heinrich-Heine-University and University Hospital Düsseldorf, Düsseldorf, Germany
| | - P Kron
- Department of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - N Lehwald-Tywuschik
- Department of Surgery (A), Heinrich-Heine-University and University Hospital Düsseldorf, Düsseldorf, Germany
| | - M Lesurtel
- Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France
| | - J P A Lodge
- Department of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - N Machairas
- 3rd Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
| | - M V Marino
- General Surgery Department, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo (PA), Abano, Italy.,General Surgery Department, Policlinico Abano Terme, Abano, Italy
| | - V Martin
- Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France
| | - A Paterson
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - J Rystedt
- Department of Surgery, Skåne University Hospital, Lund University, Lund, Sweden
| | - P Sandström
- Department of Surgery in Linköping, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
| | - A Serrablo
- Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
| | - A K Siriwardena
- Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Manchester, UK
| | - H Taflin
- Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Sweden
| | - T M van Gulik
- Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands
| | - S Yaqub
- Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway
| | - I Özden
- Department of General Surgery, Istanbul University School of Medicine, Istanbul, Turkey
| | - J M Ramia
- Hospital General Universitario de Alicante. ISABIAL Alicante, Spain
| | - C Sturesson
- Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | | |
Collapse
|
7
|
Medrano M, Soleto A, Pastor C, Rodríguez C, Carrasco R, Lapayese F, de la Peña A, Pereira A, Rincón E, Cabrera S, Ramos F, de la Cal E, Mota F, Queral V, Lopez-Heredero R, Manzanares A, Alén-Cordero C, Letellier L, Vives S, Martin V, Guern FL, Piqueras J, Kocan M. Design overview of ex-vessel components for the Wide Angle Viewing System diagnostic for ITER Equatorial Port 12. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112651] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Schiavone G, Epistolio S, Martin V, Molinari F, Barizzi J, Mazzucchelli L, Frattini M, Wannesson L. Correction to: Functional and clinical significance of ROR1 in lung adenocarcinoma. BMC Cancer 2020; 20:1196. [PMID: 33287750 PMCID: PMC7720446 DOI: 10.1186/s12885-020-07704-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Giovanna Schiavone
- Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500, Bellinzona, Switzerland.
| | - Samantha Epistolio
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Vittoria Martin
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Francesca Molinari
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Jessica Barizzi
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Luca Mazzucchelli
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Milo Frattini
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Luciano Wannesson
- Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500, Bellinzona, Switzerland
| |
Collapse
|
9
|
Schiavone G, Epistolio S, Martin V, Molinari F, Barizzi J, Mazzucchelli L, Frattini M, Wannesson L. Functional and clinical significance of ROR1 in lung adenocarcinoma. BMC Cancer 2020; 20:1085. [PMID: 33172431 PMCID: PMC7653802 DOI: 10.1186/s12885-020-07587-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Accepted: 10/29/2020] [Indexed: 11/10/2022] Open
Abstract
Background Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is normally detectable in embryonic tissues and absent in adult tissues. ROR1 was shown to inhibit apoptosis, potentiate EGFR signaling and reported to be overexpressed and associated with poor prognosis in several tumor models. This study aimed to assess the expression of ROR1 in lung adenocarcinoma (AC) patients. Methods We analyzed ROR1 expression by quantitative real-time PCR (qRT-PCR) in 56 histologically confirmed lung AC, stage I to IV, in addition we evaluated its association with TTF-1 (thyroid transcription factor-1) expression and the main molecular alterations involved in lung cancerogenesis. Results ROR1 overexpression was observed in 28.6% of the entire cohort, using a cut-off of 1, or in 51.8% of the cases using the median value as threshold. Among patients without any genetic alteration, ROR1 overexpression was observed in 34.8% considering a cut-off of 1 and 52.2% considering the median value. The distribution of ROR1 was homogeneous among the different molecular categories: we found no association of ROR1 expression and the presence of gene mutations/rearrangements or the expression of TTF-1. Conclusions ROR1 overexpression could constitute a potential therapeutic target because altered in a consistent number of lung AC, especially in cases without druggable genetic alterations. ROR1 expression is independent of classical lung cancer molecular alterations and not correlated, in a Caucasian cohort, to TTF-1 expression.
Collapse
Affiliation(s)
- Giovanna Schiavone
- Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500, Bellinzona, Switzerland.
| | - Samantha Epistolio
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Vittoria Martin
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Francesca Molinari
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Jessica Barizzi
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Luca Mazzucchelli
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Milo Frattini
- Istituto Cantonale di Patologia, Via in Selva 24, 6600, Locarno, Switzerland
| | - Luciano Wannesson
- Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500, Bellinzona, Switzerland
| |
Collapse
|
10
|
Romano E, Simon R, Martin V, Bolle S, Andraud M, Boulle G, Kissel M, Kumar T, Martelli H, Guerin F, Deutsch E, Haie-Meder C, Chargari C. OC-1045: Dose-volume effect relationships for rectal morbidity after brachytherapy for pediatric cancers. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01982-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Bordet F, Inthavong D, Fremy JM, Aspe D, Durand T, Ducher M, Fontayne N, Grignon E, Herbreteau C, Hulot S, Le Bigot C, Marengue E, Martin V, Ranneaud S, Sartre L, Vouillon B. Interlaboratory Study of a Multiresidue Gas Chromatographic Method for Determination of Organochlorine and Pyrethroid Pesticides and Polychlorobiphenyls in Milk, Fish, Eggs, and Beef Fat. J AOAC Int 2019. [DOI: 10.1093/jaoac/85.6.1398] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
An interlaboratory study was conducted to validate a gas chromatographic (GC) method for determination of 21 organochlorine pesticides, 6 pyrethroid pesticides, and 7 polychlorobiphenyl (PCB) congeners in milk, beef fat, fish, and eggs. The method was performed at low contamination levels, which represent relevant contents in food, and is an extension of the European standard (method NF-EN-1528, Parts 1–4). It enlarges the applicable scope of the reference EN method to pyrethroid pesticides and proposes the use of solid-phase extraction (SPE) as a cleanup procedure. Cryogenic extraction was made, and SPE cleanup was performed with 2 successive SPE cartridges: C18 and Florisil®. After injection of the purified extract onto a GC column, residues were measured by electron capture detection. Food samples (liquid milk, beef fat, mixed fish, and mixed eggs) were prepared, tested for homogeneity, and sent to 17 laboratories in France. Test portions were spiked with 27 pesticides and 7 PCBs at levels from 26 to 45, 4 to 27, 31 to 67, and 19 to 127 ng/g into milk, eggs, fish, and fat, respectively. Based on results for spiked samples, the relative standard deviation for repeatability ranged from 1.5 to 6.8% in milk, 3 to 39% in eggs, 4.5 to 12.2% in fish, and 7 to 13% in fat. The relative standard deviation for reproducibility ranged from 33 to 50% in milk, 29 to 59% in eggs, 31 to 57% in fish, and 30 to 62% in fat. This method showed acceptable intra- and interlaboratory precision data, as corroborated by HORRAT values at low levels of pesticide and PCB contamination. The statistical evaluation of the results was performed according to the International Organization for Standardization (ISO; ISO 3534 standard) and 5725-2 Guideline.
Collapse
Affiliation(s)
- François Bordet
- Agence Française de Sécurité Sanitaire des Aliments, Unité Contaminants de l'Environnement, 10 Rue Pierre Curie, 94704, Maisons-Alfort, Paris, France
| | - Dary Inthavong
- Agence Française de Sécurité Sanitaire des Aliments, Unité Contaminants de l'Environnement, 10 Rue Pierre Curie, 94704, Maisons-Alfort, Paris, France
| | - Jean-Marc Fremy
- Agence Française de Sécurité Sanitaire des Aliments, Unité Contaminants de l'Environnement, 10 Rue Pierre Curie, 94704, Maisons-Alfort, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Martin V, Esquembri S, Awanzino C, Nieto J, Ruiz M, Reichle R. ITER upper visible/infrared wide angle viewing system: I&C design and prototyping status. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.04.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Aleman B, Ricardi U, van der Maazen R, Meijnders P, Beijert M, Boros A, Izar F, Janus C, Levis M, Martin V, Specht L, Corning C, Clementel E, Fortpied C, Raemaekers J, Andre M, Federico M, Girinsky T. PRELIMINARY RESULTS OF A QUALITY CONTROL STUDY ON INVOLVED NODE RADIOTHERAPY IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.166_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- B.M. Aleman
- Radiation Oncology; The Netherlands Cancer Institute; Amsterdam Netherlands
| | - U. Ricardi
- Oncology; University of Turin; Turin Italy
| | | | - P. Meijnders
- Radiotherapy; GZA Ziekenhuizen campus Sint-Augustinus; Wilrijk Belgium
| | - M. Beijert
- Radiotherapy; University Medical Center Groningen; Groningen Netherlands
| | - A. Boros
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| | - F. Izar
- Radiotherapy; Institut universitaire du cancer de Toulouse; Toulouse France
| | - C.P. Janus
- Radiotherapy; Erasmus MC Cancer Institute; Rotterdam Netherlands
| | - M. Levis
- Oncology; University of Turin; Turin Italy
| | - V. Martin
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| | - L. Specht
- Oncology; Rigshospitalet; Copenhagen Denmark
| | - C. Corning
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | - E. Clementel
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | - C. Fortpied
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | | | - M.P. Andre
- Hematology; CHU UCL Mont-Godinne-Dinant; Yvoir Belgium
| | - M. Federico
- Oncology; University of Modena and Reggio Emilia; Modena Italy
| | - T. Girinsky
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| |
Collapse
|
14
|
Martin V, Fariña L, Medina K, Boido E, Dellacassa E, Mas A, Carrau F. Oenological attributes of the yeast Hanseniaspora vineaeand its application for white and red winemaking. BIO Web Conf 2019. [DOI: 10.1051/bioconf/20191202010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Flavour and some compounds associated with wine colour are known to be yeast strain-dependent. These metabolites are important for the sensory quality of wines, studies searching for increase aroma and color are a key area today in winemaking. The aim of this work was to study the oenological potential of the two main strains of Hanseniaspora vineae,native to Uruguay to better understand their successful application at winery level. It is known that these strains contribute with extracellular proteases and β-glucosidase enzyme activities that might increase cell lysis and flavor depending in grape varieties. Application and nutrient management of the process of these strains in production of white wines (Chardonnay, Macabeo and Petit Manseng) and red wine Tannat are discussed. Wines were evaluated to determine the volatile compounds composition and their effect compared to conventional processes. Low production of short and medium chain fatty acids and ethyl esters, and high production of acetate esters and isoprenoids are found compared to S. cerevisiaestrains. The most outstanding characteristic of the species H. vineaewas the production of benzenoids, phenylpropanoids and acetate esters. This behavior was reflected in the sensory evaluation, where all the fermentations performed with H. vineaewere considered superior compared to Saccharomyces cerevisiaewine strains.
Collapse
|
15
|
Quéro L, Gilardin L, Fumagalli I, Martin V, Guillerm S, Bauduceau O, Kirova YM, Hennequin C, Brice P. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma. Cancer Radiother 2019; 23:132-137. [PMID: 30733172 DOI: 10.1016/j.canrad.2018.05.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 05/03/2018] [Indexed: 11/24/2022]
Abstract
The purpose of this study was to assess efficacy and tolerance of anti-programmed death (PD)-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma. In this case series, we reported the outcome of four heavily pretreated patients with refractory Hodgkin lymphoma treated by anti-PD-1 immunotherapy and involved site radiation therapy. After a median follow-up of 13-month, all patients were alive with complete metabolic response. After radiotherapy, all four patients experienced lung toxicity, which was resolved after antibiotherapy with or without corticosteroid treatment. Anti-PD-1 immunotherapy followed by involved-site radiotherapy is feasible and showed very encouraging results in heavily pretreated patients.
Collapse
Affiliation(s)
- L Quéro
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - L Gilardin
- Department of haemato-oncology, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - I Fumagalli
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - V Martin
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - S Guillerm
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - O Bauduceau
- Radiation oncology department, Hartmann Oncology Radiotherapy Group, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France
| | - Y M Kirova
- Radiation oncology department, institut Curie, 25, rue d'Ulm, 75005 Paris, France
| | - C Hennequin
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - P Brice
- Department of haemato-oncology, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| |
Collapse
|
16
|
Martin V, Valera A, De Joffrey M, Banfi S, Mazzucchelli L. Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests. Arch Pathol Lab Med 2019; 143:411-412. [PMID: 30605369 DOI: 10.5858/arpa.2018-0904-le] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | | | - Sara Banfi
- Institute of Pathology, Locarno, Switzerland
| | | |
Collapse
|
17
|
Parchment B, Harrison J, McConnel C, Chiapetta H, Dearmin L, Beksinski C, Neveux A, Martin V, Block E, Adams-Progar A. PSV-10 Effect of feeding a yeast supplement to transition Holstein cows on colostrum quality and calf well-being. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- B Parchment
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - J Harrison
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - C McConnel
- Washington State University, Veterinary Clinical Sciences,Pullman, WA, United States
| | - H Chiapetta
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - L Dearmin
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - C Beksinski
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - A Neveux
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - V Martin
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - E Block
- Church and Dwight Animal Nutrition,Princeton, NJ, United States
| | - A Adams-Progar
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| |
Collapse
|
18
|
Bibault JE, Denis F, Roué A, Gibon D, Fumagalli I, Hennequin C, Barillot I, Quéro L, Paumier A, Mahé MA, Servagi Vernat S, Créhange G, Lapeyre M, Blanchard P, Pointreau Y, Lafond C, Huguet F, Mornex F, Latorzeff I, de Crevoisier R, Martin V, Kreps S, Durdux C, Antoni D, Noël G, Giraud P. [Siriade 2.0: An e-learning platform for radiation oncology contouring]. Cancer Radiother 2018; 22:773-777. [PMID: 30360973 DOI: 10.1016/j.canrad.2018.02.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 01/23/2018] [Accepted: 02/08/2018] [Indexed: 12/26/2022]
Abstract
PURPOSE In 2008, the French national society of radiation oncology (SFRO) and the association for radiation oncology continued education (AFCOR) created Siriade, an e-learning website dedicated to contouring. MATERIAL AND METHODS Between 2015 and 2017, this platform was updated using the latest digital online tools available. Two main sections were needed: a theoretical part and another section of online workshops. RESULTS Teaching courses are available as online commented videos, available on demand. The practical section of the website is an online contouring workshop that automatically generates a report quantifying the quality of the user's delineation compared with the experts'. CONCLUSION Siriade 2.0 is an innovating digital tool for radiation oncology initial and continuous education.
Collapse
Affiliation(s)
- J-E Bibault
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France
| | - F Denis
- Service de radiothérapie, centre Jean-Bernard, 9, rue Beauverger, 72000 Le Mans, France
| | - A Roué
- Institut national des sciences et techniques nucléaires, centre CEA de Saclay, D36, 91191 Gif-sur-Yvette, France
| | - D Gibon
- Aquilab, parc Eurasanté, biocentre Fleming, 250, rue Salvador-Allende, 59120 Loos, France
| | - I Fumagalli
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - C Hennequin
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - I Barillot
- Service d'oncologie radiothérapie, centre universitaire de cancérologie Henry-S.-Kaplan, 2, boulevard Tonnellé, 37044 Tours, France; Université François-Rabelais, 2, boulevard Tonnellé, 37044 Tours, France
| | - L Quéro
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - A Paumier
- Service d'oncologie radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Professeur-Jacques-Monod, 44805 Saint-Herblain, France
| | - M-A Mahé
- Service d'oncologie radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Professeur-Jacques-Monod, 44805 Saint-Herblain, France
| | - S Servagi Vernat
- Service d'oncologie radiothérapie, institut Jean-Godinot, 1, rue Koenig, 51100 Reims, France
| | - G Créhange
- Service d'oncologie radiothérapie, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, 21000 Dijon, France
| | - M Lapeyre
- Service d'oncologie radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63011 Clermont-Ferrand, France
| | - P Blanchard
- Service d'oncologie radiothérapie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| | - Y Pointreau
- Service de radiothérapie, centre Jean-Bernard, 9, rue Beauverger, 72000 Le Mans, France
| | - C Lafond
- Service de radiothérapie, centre Jean-Bernard, 9, rue Beauverger, 72000 Le Mans, France
| | - F Huguet
- Service d'oncologie radiothérapie, hôpital Tenon, Hôpitaux universitaires de l'Est parisien, 4, rue de la Chine, 75020 Paris, France; Université Pierre-et-Marie-Curie, 4, rue de la Chine, 75020 Paris, France
| | - F Mornex
- Service d'oncologie radiothérapie, CHU Lyon Sud, 65, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France
| | - I Latorzeff
- Service d'oncologie radiothérapie, clinique Pasteur, 1, rue de la Petite-Vitesse, 31300 Toulouse, France
| | - R de Crevoisier
- Service d'oncologie radiothérapie, centre Eugène-Marquis, avenue de la Bataille-Flandre-Dunkerque, 35700 Rennes, France
| | - V Martin
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - S Kreps
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France
| | - C Durdux
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France
| | - D Antoni
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg, France
| | - G Noël
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg, France
| | - P Giraud
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France.
| |
Collapse
|
19
|
Martin V, Valera A, De Joffrey M, Banfi S, Mazzucchelli L. Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guidelines by ASCO/College of American Pathologists Will Reduce False-Positive Tests. J Clin Oncol 2018; 36:JCO1800809. [PMID: 30346902 DOI: 10.1200/jco.18.00809] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Affiliation(s)
- Vittoria Martin
- Vittoria Martin, Alexandra Valera, Melissa De Joffrey, Sara Banfi, and Luca Mazzucchelli, Institute of Pathology, Locarno, Switzerland
| | - Alexandra Valera
- Vittoria Martin, Alexandra Valera, Melissa De Joffrey, Sara Banfi, and Luca Mazzucchelli, Institute of Pathology, Locarno, Switzerland
| | - Melissa De Joffrey
- Vittoria Martin, Alexandra Valera, Melissa De Joffrey, Sara Banfi, and Luca Mazzucchelli, Institute of Pathology, Locarno, Switzerland
| | - Sara Banfi
- Vittoria Martin, Alexandra Valera, Melissa De Joffrey, Sara Banfi, and Luca Mazzucchelli, Institute of Pathology, Locarno, Switzerland
| | - Luca Mazzucchelli
- Vittoria Martin, Alexandra Valera, Melissa De Joffrey, Sara Banfi, and Luca Mazzucchelli, Institute of Pathology, Locarno, Switzerland
| |
Collapse
|
20
|
De Dosso S, Martin V, Zanellato E, Frattini M, Saletti P. Molecular Characterization and Response to Cetuximab in a Patient with Refractory Squamous Cell Anal Carcinoma. Tumori 2018; 96:627-8. [DOI: 10.1177/030089161009600419] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
There are no standard chemotherapeutic options for patients with squamous cell anal carcinoma, relapsing and progressing on palliative cisplatin-based regimens. Similarly to other malignant conditions, monoclonal antibodies directed against the epidermal growth factor receptor may represent an attractive therapeutic strategy. Here we describe a patient who, based on molecular profile, benefited from the combination of irinotecan and cetuximab.
Collapse
Affiliation(s)
- Sara De Dosso
- Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Vittoria Martin
- Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno, Switzerland
| | - Elena Zanellato
- Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno, Switzerland
| | - Milo Frattini
- Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno, Switzerland
| | - Piercarlo Saletti
- Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| |
Collapse
|
21
|
Faivre JC, Bibault JE, Bellesoeur A, Salleron J, Wack M, Biau J, Cervellera M, Janoray G, Leroy T, Lescut N, Martin V, Molina S, Pichon B, Teyssier C, Thureau S, Mazeron JJ, Roché H, Culine S. Choosing a career in oncology: results of a nationwide cross-sectional study. BMC Med Educ 2018; 18:15. [PMID: 29334939 PMCID: PMC5769332 DOI: 10.1186/s12909-018-1117-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2017] [Accepted: 01/05/2018] [Indexed: 05/15/2023]
Abstract
BACKGROUND Little information is currently available concerning young medical students desire to pursue a career in oncology, or their career expectations. METHODS This project is a cross-sectional epidemiological study. A voluntary and anonymous questionnaire was distributed to all young oncologists studying in France between the 2nd of October 2013 and the 23rd of February 2014. RESULTS The overall response rate was 75.6%. A total of 505 young oncologists completed the questionnaire. The main determining factors in the decision to practice oncology were the cross-sectional nature of the field (70.8%), the depth and variety of human relations (56.3%) and the multi-disciplinary field of work (50.2%). Most residents would like to complete a rotation outside of their assigned region (59.2%) or abroad (70.2%) in order to acquire additional expertise (67.7%). In addition, most interns would like to undertake a fellowship involving care, teaching and research in order to hone their skills (85.7%) and forge a career in public hospitals (46.4%). Career prospects mainly involve salaried positions in public hospitals. Many young oncologists are concerned about their professional future, due to the shortage of openings (40.8%), the workload (52.8%) and the lack of work-life balance (33.4%). CONCLUSIONS This investigation provides a comprehensive profile of the reasons young oncologists chose to pursue a career in oncology, and their career prospects.
Collapse
Affiliation(s)
- J. C. Faivre
- Academic Radiation Oncology & Brachytherapy Department, Lorraine Institute of Cancerology - Alexis-Vautrin Comprehensive Cancer Centre, 6 avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France
- Radiation Oncology Department, University Hospital of Paris (Georges Pompidou European Hospital), 20 rue Leblanc, 75015 Paris, France
- Academic Department of Radiation Therapy & Brachytherapy, Lorraine Institute of Cancerology – Alexis-Vautrin CLCC [Centre de lutte contre le cancer – Cancer Centre] – Unicancer, 6 avenue de Bourgogne –CS 30 519, cedex F-54 511 Vandoeuvre-lès-Nancy, France
| | - J. E. Bibault
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Paris (Georges Pompidou European Hospital), 20 rue Leblanc, 75015 Paris, France
- Paris Descartes University, 12 rue de l’Ecole de médicine, 75006 Paris, France
| | - A. Bellesoeur
- Medical Oncology Department, University Hospital of Paris (Teaching Hospital Cochin), 27 rue du Faubourg Saint Jacques, 75014 Paris, France
- French Resident’s and Fellow’s Association for Teaching and Research in Oncology (AERIO), 149 avenue du Maine, 75014 Paris, France
| | - J. Salleron
- Biostatistics Department, Lorraine Institute of Cancerology - Alexis-Vautrin Comprehensive Cancer Centre, 6 avenue de Bourgogne, F-54519 Vandœuvre-lès-Nancy, France
| | - M. Wack
- Biostatistics and Epidemiology Department, University Hospital of Nancy, 9 avenue de la Forêt de Haye, 54505 Vandoeuvre-lès-nancy, France
| | - J. Biau
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, Jean-Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63000 Clermont-Ferrand, France
- University of Auvergne, 28 place Henri Dunant, 63000 Clermont-Ferrand, France
| | - M. Cervellera
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, Jean Godinot Comprehensive Cancer Centre, 1 rue du Général Koenig, 51726 Reims, France
| | - G. Janoray
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- S. Kaplan Cancer Centre, Radiation Oncology Department, University Hospital of Tours, 2 boulevard Tonnelé, 37000 Tours, France
| | - T. Leroy
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Academic Radiation Oncology Department, Oscar Lambret Comprehensive Cancer Centre, 3 rue Frédéric Combemale, 59000 Lille, France
| | - N. Lescut
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Besançon, 3 boulevard Fleming, 25000 Besançon, France
| | - V. Martin
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Paris (Kremlin-Bicêtre Hospital), 78 rue du Général Leclerc, 94270 Paris, France
- Paris Sud University, 63 rue Gabriel Péri, 94276 Orsay, France
| | - S. Molina
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers, France
| | - B. Pichon
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, René-Gauducheau Comprehensive Cancer Centre, boulevard Jacques Monod, 44805 Nantes, Saint-Herblain France
| | - C. Teyssier
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Besançon, 3 boulevard Fleming, 25000 Besançon, France
| | - S. Thureau
- Radiation Oncology & Medical Physics Department, Henri-Becquerel Comprehensive Cancer Centre, rue d’Amiens, 76000 Rouen, France
- EA4108 QuantIf Litis, University of Rouen, 22 boulevard Gambetta, 76000 Rouen, France
| | - J. J. Mazeron
- Radiation Oncology Department, University Hospital of Paris (Pitié-Salpétrière Hospital), 83 boulevard de l’hôpital, 75013 Paris, France
- University Pierre et Marie Curie, 4 place Jussieu, 75005 Paris, France
| | - H. Roché
- Oncopole Toulouse, Claudius Regaud Comprehensive Cancer Centre, 1 avenue Irène Joliot-Curie, 31059 Toulouse, France
- University of Toulouse, 37 allée Jules Guesde, 36000 Toulouse, France
| | - S. Culine
- Medical Oncology Department, University Hospital of Paris (Saint-Louis Hospital), 1 avenue Claude Vellefaux, 75010 Paris, France
- Paris Diderot University, 16 rue Huchard, 75018 Paris, France
| |
Collapse
|
22
|
Almeras T, Schreiber P, Fournel S, Martin V, Nicolas CS, Fontaine C, Lesbros C, Gueguen S. Comparative efficacy of the Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV vaccines against infection with circulating feline Calicivirus. BMC Vet Res 2017; 13:300. [PMID: 29017551 PMCID: PMC5635571 DOI: 10.1186/s12917-017-1217-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 10/03/2017] [Indexed: 11/17/2022] Open
Abstract
Background Feline calicivirus (FCV) is a common virus, found worldwide, mainly responsible for chronic ulceroproliferative faucitis and periodontitis. This virus has a high mutation rate, leading to the presence of numerous FCV strains in the field. The objectives of this study was to evaluate and compare the efficacy of two vaccines (Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV), which differ by their nature (live vs. inactivated) and the vaccinal strains, against circulating FCV strains. Thirty 9-week-old specific pathogen free (SPF) kittens were thus randomised into 3 groups and were either not vaccinated (control) or vaccinated (2 injections, 3 weeks apart) with one of the vaccines. Four weeks after the second injection of primary vaccination, the cats were inoculated with a pathogenic strain representative of the ones circulating in Europe (FCV-FR4_01) and followed for 2 weeks. Results After challenge, significant differences (p < 0.05) between control cats and cats vaccinated with Leucofeligen™ FeLV/RCP or Purevax™ RCP FeLV were observed for body weight variation, rectal temperature rise and maximum clinical scores, reflecting the intensity of the signs (83% and 67% lower in the respective vaccinated groups than in the control group). Significant differences were observed between the vaccinated groups, as cats vaccinated with Leucofeligen™ FeLV/RCP had a lower temperature rise (p < 0.05 at days post-challenge 3 to 5) and lower virus shedding titres (p < 0.05 at days post-challenge 8, 9 and 11) than cats vaccinated with Purevax™ RCP FeLV. Finally, only cats vaccinated with Leucofeligen™ FeLV/RCP had a significantly lower cumulative score, reflecting the intensity and duration of calicivirosis clinical signs, than the control cats (77% lower vs. 62% lower for cats vaccinated with Purevax™ RCP FeLV). Conclusions Both vaccines, Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV, were found to be efficacious in reducing clinical signs induced by FCV-FR4_01, a FCV strain representative of the circulating ones. However, cats vaccinated with Leucofeligen™ FeLV/RCP were able to control the infection more efficiently than those vaccinated with Purevax™ RCP FeLV, as evidenced by the shorter duration of clinical signs and lower viral titre in excretions.
Collapse
Affiliation(s)
- T Almeras
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - P Schreiber
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - S Fournel
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - V Martin
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - C S Nicolas
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - C Fontaine
- Virbac, 13ème rue, LID, 06511, Carros, France.
| | - C Lesbros
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - S Gueguen
- Virbac, 13ème rue, LID, 06511, Carros, France
| |
Collapse
|
23
|
Hennequin C, Fumagalli I, Martin V, Quero L. [Combination of radiotherapy and androgen deprivation therapy for localized prostate cancer]. Cancer Radiother 2017; 21:462-468. [PMID: 28870416 DOI: 10.1016/j.canrad.2017.07.045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 07/02/2017] [Indexed: 10/18/2022]
Abstract
Combination of radiotherapy and androgen deprivation is now considered as the standard of care for patients with a localized prostate cancer but poor prognosis factors. Two groups of randomized trials have led to this recommendation: some have compared radiotherapy alone versus hormonal treatment and radiotherapy: these trials demonstrated, now with a long follow-up, an improvement in 10-year survival for the combined treatment. Three recent trials compared androgen deprivation alone or combined with radiotherapy; a benefit in survival was also demonstrated in favour of the combination. Some questions remained concerning the optimal duration of hormonal treatment, in view of its potential side effects. Patients in the intermediate prognostic groups could receive a short-term androgen deprivation, but those with a high Gleason score must be treated with a long-term hormonal treatment. Modalities of radiotherapy, regarding volumes and dose must also be précised in the next years.
Collapse
Affiliation(s)
- C Hennequin
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.
| | - I Fumagalli
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France
| | - V Martin
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France
| | - L Quero
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France
| |
Collapse
|
24
|
Rossignon F, Martin V, Salles J, Patrac V, Le Bacquer O, Berry A, Pion A, Giraudet C, Montaurier C, Ratel S, François B, Roussillat C, Walrand S, Combe K, Domingues Faria C, Boirie Y, Guillet C. L’apport protéique a-t-il une influence sur la composition corporelle et la fonctionnalité musculaire en situation de surnutrition lipidique ? NUTR CLIN METAB 2017. [DOI: 10.1016/j.nupar.2017.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Rodriguez-Blanco J, Pednekar L, Penas C, Li B, Martin V, Long J, Lee E, Weiss WA, Rodriguez C, Mehrdad N, Nguyen DM, Ayad NG, Rai P, Capobianco AJ, Robbins DJ. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. Oncogene 2017; 36:6306-6314. [PMID: 28714964 DOI: 10.1038/onc.2017.232] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 06/02/2017] [Accepted: 06/05/2017] [Indexed: 12/24/2022]
Abstract
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodegib-resistant reservoir of tumor-propagating cells. We isolated such tumor-propagating cells from a mouse model of SHH-subgroup MB and grew them as sphere cultures. These cultures were enriched for the MB progenitor marker SOX2 and formed tumors in vivo. Moreover, while their ability to self-renew was resistant to SHH inhibitors, as has been previously suggested, this self-renewal was instead WNT-dependent. We show here that loss of Trp53 activates canonical WNT signaling in these SOX2-enriched cultures. Importantly, a small molecule WNT inhibitor was able to reduce the propagation and growth of SHH-subgroup MB in vivo, in an on-target manner, leading to increased survival. Our results imply that the tumor-propagating cells driving the growth of bulk SHH-dependent MB are themselves WNT dependent. Further, our data suggest combination therapy with WNT and SHH inhibitors as a therapeutic strategy in patients with SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients treated with vismodegib.
Collapse
Affiliation(s)
- J Rodriguez-Blanco
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - L Pednekar
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - C Penas
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - B Li
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - V Martin
- Morphology and Cell Biology Department, University of Oviedo, Asturias, Spain
| | - J Long
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - E Lee
- Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA
| | - W A Weiss
- Department of Neurobiology, University of California, San Francisco, CA, USA
| | - C Rodriguez
- Morphology and Cell Biology Department, University of Oviedo, Asturias, Spain
| | - N Mehrdad
- Department of Pathology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - D M Nguyen
- Division of Cardiothoracic Surgery, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - N G Ayad
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - P Rai
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.,Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - A J Capobianco
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - D J Robbins
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| |
Collapse
|
26
|
Siano M, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. Oncologist 2017; 22:782-e70. [PMID: 28592616 PMCID: PMC5507653 DOI: 10.1634/theoncologist.2017-0069] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 04/04/2017] [Indexed: 11/20/2022] Open
Abstract
Lessons Learned. Panitumumab shows activity in terms of disease control rate and preventing disease progression but not for tumor shrinkage in head and neck squamous cell cancer for second‐line treatment. Epidermal growth factor receptor (EGFR) copy number gain, a property of tumor cells that theoretically could identify patients more likely to experience disease response, was common among patients having disease control. Our trial, given the lower toxicity with an every‐2‐week schedule, provides guidance for future trials, for example, in combinations of immune therapies and anti‐EGFR‐antibodies.
Background. The objective of this study was to investigate the efficacy and safety of panitumumab (anti‐epidermal growth factor receptor [EGFR] antibody) given as a single agent in platinum‐pretreated head and neck squamous cell cancer (HNSCC). Methods. Patients with advanced HNSCC previously treated with platinum‐containing therapy were included. Panitumumab was administered intravenously every 2 weeks at a dose of 6 mg/kg. Primary endpoint was overall response rate (ORR) according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; secondary endpoints were progression‐free survival (PFS) and safety. A Simon's two‐step design was chosen; 4 partial remissions (PR) in the first 32 patients were required for continuing to step two. An exploratory biomarker analysis was performed. Results. Thirty‐three patients were enrolled. Two patients obtained a PR for an ORR of 6%, and 15 (45%) showed stable disease (SD) for at least 2 months, resulting in a 51% disease control rate. Median PFS was 2.6 months (95% confidence interval [CI]: 1.7–3.7), while median OS was 9.7 months (95% CI: 6.3–17.2). The most frequent adverse drug reactions were cutaneous rash (64%) and hypomagnesemia (55%). Overall, 30% of patients experienced grade 3/4 adverse events. No infusion‐related reactions occurred. EGFR copy number gain (CNG) was more frequent in patients who benefitted from panitumumab. Two uncommon KRAS mutations (G48E, T50I) and 3 canonical PIK3CA mutations (all E545K) were detected. High‐risk HPV16 was found in 10 patients and EGFR CNG in 13 treated patients. EGFR CNG seems to be more frequent in individuals with at least SD compared with patients with progressive disease (59% vs. 30%). PFS for patients with EGFR CNG was 4.6 months (95% CI: 1.0–9.2 months) and 1.9 months (95% CI: 1.0–3.2 months) for patients without CNG (p = .02). Conclusion. Panitumumab monotherapy in pretreated HNSCC patients was well tolerated but moderately active. We observed a considerable disease control rate. Future strategies with this agent comprise right patient selection through the identification of reliable biomarkers and gene signatures predicting response and, considering good tolerability and convenience, combination strategies with novel agents and immune therapeutic agents.
Collapse
Affiliation(s)
- Marco Siano
- Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Francesca Molinari
- Institute of Pathology, Laboratory of Molecular Pathology, Locarno, Switzerland
| | - Vittoria Martin
- Institute of Pathology, Laboratory of Molecular Pathology, Locarno, Switzerland
| | - Nicolas Mach
- Clinical Research Unit of the Dr. Henri Dubois-Ferrière, University Hospital, Geneva, Switzerland
| | - Martin Früh
- Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Stefania Freguia
- Institute of Pathology, Laboratory of Molecular Pathology, Locarno, Switzerland
| | - Irene Corradino
- Clinical Trial Unit, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
| | - Michele Ghielmini
- Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland
| | - Milo Frattini
- Institute of Pathology, Laboratory of Molecular Pathology, Locarno, Switzerland
| | - Vittoria Espeli
- Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland
| |
Collapse
|
27
|
Ferguson S, Gotlieb W, Gien L, Giede C, Samouelian V, Steed H, Renkosinski B, Abitbol J, Warkus T, Le T, Martin V, Panzarella T, Covens A, Bernardini M. GOC2: A multicenter prospective trial comparing open, laparoscopic and robotic surgical outcomes in women with endometrial cancer. Part B: Patient-reported outcomes. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Dávila-Batista V, Carriedo D, Díez F, Pueyo Bastida A, Martínez Durán B, Martin V. [Estimation of the population attributable fraction due to obesity in hospital admissions for flu valued according to Body Mass Index (BMI) and CUN-BAE]. Semergen 2017; 44:100-106. [PMID: 28506756 DOI: 10.1016/j.semerg.2017.01.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 01/11/2017] [Accepted: 01/12/2017] [Indexed: 11/17/2022]
Abstract
INTRODUCTION The obesity pandemic together with the influenza pandemic could lead to a significant burden of disease. The body mass index (BMI) does not discriminate obesity appropriately. The CUN-BAE has recently been used as an estimate of body fatness for Caucasians, including BMI, gender, and age. The aim of this study is to assess the population attributable fraction of hospital admissions due to influenza, due to the body fatness measured with the BMI, and the CUN-BAE. METHODS A multicentre study was conducted using matched case-controls. Cases were hospital admissions with the influenza confirmed by the RT-PCR method between 2009 and 2011. The risk of hospital admission and the population attribuible fraction were calculated using the BMI or the CUN-BAE for each adiposity category in a conditional logical regression analysis adjusted for confounding variables. The analyzes were estimated in the total sample, in unvaccinated people, and those less than 65 years-old. RESULTS A total of 472 hospitalised cases and 493 controls were included in the study. Compared to normal weight, the aOR of influenza hospital admissions increases with each level of BMI (aOR=1.26; 2.06 and 11.64) and CUN-BAE (aOR=2.78; 4.29; 5.43 and 15.18). The population attributable fraction of influenza admissions using CUN-BAE is 3 times higher than that estimated with BMI (0,72 vs. 0,27), with the differences found being similar the non-vaccinated and under 65 year-olds. CONCLUSION The BMI could be underestimating the burden of disease attributable to obesity in individuals hospitalised with influenza. There needs to be an appropriate assessment of the impact of obesity and vaccine recommendation criteria.
Collapse
Affiliation(s)
- V Dávila-Batista
- Grupo de Investigación interacciones gen-ambiente y salud (GIGAS), Universidad de León, León, España
| | - D Carriedo
- Complejo Asistencial Universitario de León, León, España
| | - F Díez
- Complejo Asistencial Universitario de León, León, España
| | | | | | - V Martin
- Grupo de Investigación interacciones gen-ambiente y salud (GIGAS), Universidad de León, León, España; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, España.
| |
Collapse
|
29
|
Guillerm S, Bourstyn E, Itti R, Fumagalli I, Martin V, Cahen-Doidy L, Quero L, Giacchetti S, Cuvier C, Espié M, Hennequin C. EP-1150: Preliminary results of Intra-Operative RadioTherapy in old women with good prognostic features. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31586-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
30
|
Fulciniti F, Barizzi J, Martin V, Tarallo V, Ermanni S. Synovial sarcoma metastatic to the parotid gland: A possible pitfall in salivary gland fine needle aspiration cytology. Report of a case with immunocytochemical and fluorescence in situ hybridization findings. Diagn Cytopathol 2017; 45:834-836. [PMID: 28421710 DOI: 10.1002/dc.23725] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Revised: 03/21/2017] [Accepted: 03/30/2017] [Indexed: 11/11/2022]
Abstract
We report one case of metastatic synovial sarcoma (SS) to the parotid gland in a 93-year-old male. The patient had undergone upper left pulmonary lobectomy with mediastinal lymphadenectomy for SS of the lung 5 years before. The cytopathologic presentation and the immunocytochemical findings on the FNA sample were suggestive of a spindle cell myoepithelioma, while a SYT rearrangement was identified by a FISH performed on a cytological smear of the lesion. The diagnosis was further confirmed also by positive immunocytochemical expression of TLE1 on a section from the obtained cell block. The cytologic and immunophenotypic findings are shortly discussed in view of the reported immunophenotypic inconsistency of SS and of its differential diagnosis with spindle cell myoepithelioma of the salivary glands.The importance of the recently described TLE1 staining and its close correlation to SYT rearrangement is briefly discussed.
Collapse
Affiliation(s)
| | | | - Vittoria Martin
- Istituto Cantonale di Patologia, Locarno, Switzerland.,Molecular Pathology Laboratory, Istituto Cantonale di Patologia, Locarno, Switzerland
| | | | - Stefano Ermanni
- ENT Department, Ospedale Regionale di Mendrisio, Mendrisio, Switzerland
| |
Collapse
|
31
|
Verney J, Martin V, Ratel S, Chavanelle V, Bargetto M, Etienne M, Chaplais E, Le Ruyet P, Bonhomme C, Combaret L, Guillet C, Boisseau N, Sirvent P, Dardevet D. Soluble Milk Proteins Improve Muscle Mass Recovery after Immobilization-Induced Muscle Atrophy in Old Rats but Do not Improve Muscle Functional Property Restoration. J Nutr Health Aging 2017; 21:1133-1141. [PMID: 29188872 DOI: 10.1007/s12603-016-0855-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVES Effect of 3 different dairy protein sources on the recovery of muscle function after limb immobilization in old rats. DESIGN Longitudinal animal study. SETTING Institut National de la Recherche Agronomique (INRA). The study took part in a laboratory setting. INTERVENTION Old rats were subjected to unilateral hindlimb immobilization for 8 days and then allowed to recover with 3 different dietary proteins: casein, soluble milk proteins or whey proteins for 49 days. MEASUREMENTS Body weight, muscle mass, muscle fibre size, isometric, isokinetic torque, muscle fatigability and muscle oxidative status were measured before and at the end of the immobilization period and during the recovery period i.e 7, 21, 35 and 49 days post immobilization. RESULTS In contrast to the casein diet, soluble milk proteins and whey proteins were efficient to favor muscle mass recovery after cast immobilization during aging. By contrast, none of the 3 diary proteins was able to improve muscle strength, power and fatigability showing a discrepancy between the recovery of muscle mass and function. However, the soluble milk proteins allowed a better oxidative capacity in skeletal muscle during the rehabilitation period. CONCLUSION Whey proteins and soluble milk proteins improve muscle mass recovery after immobilization-induced muscle atrophy in old rats but do not allow muscle functional property restoration.
Collapse
Affiliation(s)
- J Verney
- Dominique Dardevet, INRA, Unité de Nutrition Humaine (UNH, UMR 1019), CRNH Auvergne, France,
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Chabert I, E. Barat, Dhermain F, Poisson F, Ammari S, Martin V, Buvat I, D. Lazaro, Deutsch E, Robert C. 12. Analysis of the impact of rCBV map threshold to predict tumor recurrence in high-grade gliomas. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.11.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
33
|
Chabert I, Belladjou I, Poisson F, Dhermain F, Martin V, Ammari S, Vauclin S, Pineau P, Buvat I, Deutsch E, Robert C. EP-1875: Correlation between MRI-based hyper-perfused areas and tumor recurrence in high-grade gliomas. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33126-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Stragier E, Martin V, Davenas E, Poilbout C, Mongeau R, Corradetti R, Lanfumey L. Brain plasticity and cognitive functions after ethanol consumption in C57BL/6J mice. Transl Psychiatry 2015; 5:e696. [PMID: 26670281 PMCID: PMC5068583 DOI: 10.1038/tp.2015.183] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 09/23/2015] [Accepted: 10/09/2015] [Indexed: 12/20/2022] Open
Abstract
Acute or chronic administrations of high doses of ethanol in mice are known to produce severe cognitive deficits linked to hippocampal damage. However, we recently reported that chronic and moderate ethanol intake in C57BL/6J mice induced chromatin remodeling within the Bdnf promoters, leading to both enhanced brain-derived neurotrophic factor (BDNF) expression and hippocampal neurogenesis under free-choice protocol. We performed here a series of cellular and behavioral studies to analyze the consequences of these modifications. We showed that a 3-week chronic free-choice ethanol consumption in C57BL/6J mice led to a decrease in DNA methylation of the Bdnf gene within the CA1 and CA3 subfields of the hippocampus, and upregulated hippocampal BDNF signaling pathways mediated by ERK, AKT and CREB. However, this activation did not affect long-term potentiation in the CA1. Conversely, ethanol intake impaired learning and memory capacities analyzed in the contextual fear conditioning test and the novel object recognition task. In addition, ethanol increased behavioral perseveration in the Barnes maze test but did not alter the mouse overall spatial capacities. These data suggested that in conditions of chronic and moderate ethanol intake, the chromatin remodeling leading to BDNF signaling upregulation is probably an adaptive process, engaged via epigenetic regulations, to counteract the cognitive deficits induced by ethanol.
Collapse
Affiliation(s)
- E Stragier
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - V Martin
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - E Davenas
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - C Poilbout
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - R Mongeau
- Université Paris Descartes, UMR S894, Paris, France
- Pharmacologie de la circulation cérébrale EA 4475, Faculté de pharmacie Université Paris Descartes, Paris, France
| | - R Corradetti
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - L Lanfumey
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| |
Collapse
|
35
|
Sahnane N, Frattini M, Bernasconi B, Zappa F, Schiavone G, Wannesson L, Antonelli P, Balzarini P, Sessa F, Mazzucchelli L, Tibiletti MG, Martin V. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. Clin Lung Cancer 2015; 17:56-61. [PMID: 26381283 DOI: 10.1016/j.cllc.2015.08.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Revised: 07/27/2015] [Accepted: 08/11/2015] [Indexed: 01/15/2023]
Abstract
INTRODUCTION In lung adenocarcinoma (ADC), anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements are mutually exclusive with epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. However, the existence of double-positive (DP) patients have been sporadically described. We identified DP cases in therapy-naive ALK-rearranged ADC and characterized the biology of these tumors to better understand the clinical response to tyrosine kinase inhibitors (TKIs). MATERIALS AND METHODS We selected 42 ALK-positive ADCs from a multicentric series of 301 cases of ADCs. A mutational analysis was performed using Sanger and/or pyrosequencing to address exons 18-21 of EGFR and codons 12-13 of the KRAS gene. In addition, the KRAS and EGFR copy number was investigated using fluorescent in situ hybridization. DP patients were treated with TKIs, and their response was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria. RESULTS Eight of 42 ALK-positive ADCs (19%) demonstrated a concomitant mutation in the EGFR (3 cases) or KRAS (5 cases) genes and were classified as DP. All DP cases displayed copy number gains in the EGFR or KRAS gene because of polysomy or gene amplification. In the latter cases, a mutant allele-specific imbalance was observed. Four patients were treated with TKIs. The 2 EGFR-mutant DP patients demonstrated a better response to crizotinib compared with erlotinib. The 2 KRAS-mutant DP patients experienced opposite responses to crizotinib. CONCLUSION The incidence of DP ADC is not negligible. Patients with ALK/EGFR might benefit more from crizotinib compared with erlotinib administration, although the efficacy of TKIs in patients with ALK/KRAS remains unclear. An integrated targeted therapy should be considered for patients with DP ADC.
Collapse
Affiliation(s)
- Nora Sahnane
- Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy.
| | | | - Barbara Bernasconi
- Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy
| | - Francesco Zappa
- Department of Oncology, Clinica Luganese, Lugano, Switzerland
| | | | | | - Paola Antonelli
- Department of Oncology, Ospedale di Busto Arsizio, Busto Arsizio, Italy
| | - Piera Balzarini
- Department of Pathology, University of Brescia, Brescia, Italy
| | - Fausto Sessa
- Department of Surgical and Morphological Sciences, University of Insubria, Varese, Italy
| | | | | | | |
Collapse
|
36
|
Martin V, Cuenca X, Lopez S, Albertini AF, Lang P, Simon JM, Hémery CG, Feuvret L, Mazeron JJ. Iris metastasis from prostate carcinoma: A case report and review of the literature. Cancer Radiother 2015; 19:331-3. [DOI: 10.1016/j.canrad.2014.12.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 12/15/2014] [Accepted: 12/24/2014] [Indexed: 11/25/2022]
|
37
|
Bartels A, Martin V, Bidoli E, Steigmeier-Raith S, Brühschwein A, Reese S, Köstlin R, Erhard M. Brachycephalic problems of pugs relevant to animal welfare. Anim Welf 2015. [DOI: 10.7120/09627286.24.3.327] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
38
|
Kamsu-Kom L, Bidault F, Mazeron R, Baratiny C, Martin V, Maroun P, Dumas I, Guemnie-Tafo A, Martinetti F, Gerbaulet A, Chargari C, Haie-Meder C. Clinical Experience with Pulse Dose Rate Brachytherapy for Conservative Treatment of Penile Carcinoma and Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol) 2015; 27:387-93. [DOI: 10.1016/j.clon.2015.03.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Revised: 03/11/2015] [Accepted: 03/26/2015] [Indexed: 10/23/2022]
|
39
|
Mozzi A, Forcella M, Riva A, Difrancesco C, Molinari F, Martin V, Papini N, Bernasconi B, Nonnis S, Tedeschi G, Mazzucchelli L, Monti E, Fusi P, Frattini M. NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels. Glycobiology 2015; 25:855-68. [DOI: 10.1093/glycob/cwv026] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Accepted: 04/22/2015] [Indexed: 12/31/2022] Open
|
40
|
Abstract
HER2 is a well-recognized mediator of the cancerogenic process. It is dysregulated in a wide range of solid tumors, mainly via protein overexpression and/or gene amplification, thus making HER2 an attractive target for tailored treatment. The anti-HER2 therapy trastuzumab was approved for the treatment of HER2-positive metastatic breast cancer patients more than 10 years ago. Since then, trastuzumab and other HER2-inhibitors have been entered into clinical practice for the treatment of breast cancer and, more recently, have been approved to treat HER2-positive metastatic gastric cancers. Currently, HER2-targeted therapies are under evaluation in other tumor types. Due to the relevance of proper patient selection, the accurate assessment of HER2 status is fundamental. This review will discuss the established knowledge and novel insights into the HER2 story, mainly focusing on breast, gastric and colorectal cancers, as well as providing a brief overview of salivary gland, bladder, ovarian and lung tumors.
Collapse
Affiliation(s)
- Vittoria Martin
- Institute of Pathology, Via in Selva 24, 6600 Locarno, Switzerland
| | | | | | | |
Collapse
|
41
|
Zghal F, Cottin F, Kenoun I, Rebaï H, Moalla W, Dogui M, Tabka Z, Martin V. Improved tolerance of peripheral fatigue by the central nervous system after endurance training. Eur J Appl Physiol 2015; 115:1401-15. [PMID: 25681110 DOI: 10.1007/s00421-015-3123-y] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Accepted: 02/03/2015] [Indexed: 11/28/2022]
Abstract
PURPOSE The purposes of this study were to evaluate the effect of endurance training on central fatigue development and recovery. METHODS A control group was compared to a training group, which followed an 8-week endurance-training program, consisting in low-force concentric and isometric contractions. Before (PRE) and after (POST) the training period, neuromuscular function of the knee extensor (KE) muscles was evaluated before, immediately after and during 33 min after an exhausting submaximal isometric task at 15 % of the maximal voluntary contraction (MVC) force. After training, the trained group performed another test at iso-time, i.e., with the task maintained until the duration completed before training was matched (POST2). The evaluation of neuromuscular function consisted in the determination of the voluntary activation level during MVCs, from peripheral nerve electrical (VAPNS) and transcranial magnetic stimulations (VATMS). The amplitude of the potentiated twitch (Pt), the evoked [motor evoked potentials, cortical silent period (CSP)] and voluntary EMG activities were also recorded on the KE muscles. RESULTS Before training, the isometric task induced significant reductions of VAPNS, VATMS and Pt, and an increased CSP. The training period induced a threefold increase of exercise duration, delayed central fatigue appearance, as illustrated by the absence of modification of VAPNS, VATMS and CSP after POST2. At POST, central fatigue magnitude and recovery were not modified but Pt reduction was greater. CONCLUSION These results suggest that central fatigue partially adapts to endurance training. This adaptation principally translates into improved tolerance of peripheral fatigue by the central nervous system.
Collapse
Affiliation(s)
- F Zghal
- UBIAE (INSERM U902), Faculty of Sport Sciences, Val d'Essonne University, Evry, France
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Bourourou M, Holzinger M, Elouarzaki K, Le Goff A, Bossard F, Rossignol C, Djurado E, Martin V, Curtil D, Chaussy D, Maaref A, Cosnier S. Laccase wiring on free-standing electrospun carbon nanofibres using a mediator plug. Chem Commun (Camb) 2015; 51:14574-7. [DOI: 10.1039/c5cc03906a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The enzyme laccase was wired on a free-standing electrospun carbon fiber mat using a cross-linker plug based on the pyrene modified electron shuttle ABTS.
Collapse
Affiliation(s)
- M. Bourourou
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
- Laboratoire des Interfaces et des Matériaux Avancés
| | - M. Holzinger
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| | - K. Elouarzaki
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| | - A. Le Goff
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| | - F. Bossard
- Univ. Grenoble Alpes – CNRS
- LRP
- F-38000 Grenoble
- France
| | | | - E. Djurado
- Univ. Grenoble Alpes
- LEPMI
- F-38000 Grenoble
- France
| | - V. Martin
- Univ. Grenoble Alpes
- LEPMI
- F-38000 Grenoble
- France
| | - D. Curtil
- LGP2 (Laboratory of Pulp and Paper Science and Graphic Arts)
- Grenoble INP-Pagora/CNRS UMR
- 38402 Grenoble
- France
| | - D. Chaussy
- LGP2 (Laboratory of Pulp and Paper Science and Graphic Arts)
- Grenoble INP-Pagora/CNRS UMR
- 38402 Grenoble
- France
| | - A. Maaref
- Laboratoire des Interfaces et des Matériaux Avancés
- Faculté des Sciences de Monastir-Université de Monastir
- Tunisia
| | - S. Cosnier
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| |
Collapse
|
43
|
Rodriguez-Blanco J, Bin L, Martin V, Lee E, Rodriguez C, Capobianco A, Robbins DJ. SC-28 * NOVEL INHIBITORS ON HEDGEHOG PATHWAY TO PREVENT MEDULLOBLASTOMA RELAPSE. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou275.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Lechauve J, Perrault H, Aguilaniu B, Isner-Horobeti M, Martin V, Coudeyre E, Richard R. Breathing patterns during eccentric exercise. Respir Physiol Neurobiol 2014; 202:53-8. [DOI: 10.1016/j.resp.2014.07.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2014] [Revised: 07/05/2014] [Accepted: 07/08/2014] [Indexed: 11/29/2022]
|
45
|
Mazeron R, Castelnau-Marchand P, Dumas I, Martin V, Kom LK, Farha G, Martinetti F, Tailleur A, Lefkopopoulos D, Haie-Méder C. Impact de l’étalement et de l’escalade de dose sur le contrôle local des cancers du col de l’utérus après chimioradiothérapie suivie de curiethérapie guidée par l’image. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, Martin V, Frattini M, Aglietta M, Leone F. Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes Cancer 2014; 53:1033-40. [PMID: 25231053 DOI: 10.1002/gcc.22212] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 08/08/2014] [Indexed: 01/30/2023] Open
Abstract
ROS1 rearrangements have been detected in a variety of tumors and are considered as suitable targets of anticancer therapies. We developed a new, quick, specific, and sensitive PCR test to screen for the FIG-ROS1 fusion and applied it to a series of Italian patients with bile duct carcinoma (BTC). Formalin-fixed, paraffin-embedded tissues, derived from 65 Italian BTC patients, and six cell lines were analyzed by nested PCR to investigate the prevalence of a previously reported FIG-ROS1 fusion. The specificity and sensitivity of nested PCR were investigated in FIG-ROS1 positive U118MG cells in reconstitution experiments with peripheral blood mononuclear cells. We found that six out of 65 (9%) BTC patients were positive for the FIG-ROS1 fusion, comprising two out of 14 (14%) gallbladder carcinoma (GBC) patients and four out of 25 (16%) extrahepatic cholangiocarcinoma (ECC) patients. None of the 26 intrahepatic cholangiocarcinoma cases harbored the FIG-ROS1 fusion. All the cell lines were negative for this variant. In conclusion, 14-16% of GBC and ECC were positive for FIG-ROS1. This may have clinical implications, since these patients will potentially benefit from the treatment with specific ROS1 inhibitors.
Collapse
Affiliation(s)
- Caterina Peraldo Neia
- Department of Oncology, University of Turin Medical School, IRCCS-Candiolo, Turin, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Riva A, Mozzi A, Forcella M, Difrancesco C, Molinari F, Papini N, Bernasconi B, Martin V, Mazzucchelli L, Monti E, Fusi P, Frattini M. Neu3 Activity Enhances Egfr Activation Without Affecting Egfr Expression. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu359.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Mazeron R, Dumas I, Martin V, Martinetti F, Benhabib-Boukhelif W, Gensse MC, Chargari C, Guemnie-Tafo A, Haie-Méder C. [Pulsed-dose rate brachytherapy in cervical cancers: why, how?]. Cancer Radiother 2014; 18:447-51. [PMID: 25155782 DOI: 10.1016/j.canrad.2014.06.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2014] [Revised: 06/24/2014] [Accepted: 06/26/2014] [Indexed: 10/24/2022]
Abstract
The end of the production of 192 iridium wires terminates low dose rate brachytherapy and requires to move towards pulsed-dose rate or high-dose rate brachytherapy. In the case of gynecological cancers, technical alternatives exist, and many teams have already taken the step of pulsed-dose rate for scientific reasons. Using a projector source is indeed a prerequisite for 3D brachytherapy, which gradually installs as a standard treatment in the treatment of cervical cancers. For other centers, this change implies beyond investments in equipment and training, organizational consequences to ensure quality.
Collapse
Affiliation(s)
- R Mazeron
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
| | - I Dumas
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - V Martin
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - F Martinetti
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - W Benhabib-Boukhelif
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - M-C Gensse
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - C Chargari
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - A Guemnie-Tafo
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - C Haie-Méder
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| |
Collapse
|
49
|
Curioni-Fontecedro A, Martin V, Vogetseder A, Knuth A, Moch H, Soldini D, Tinguely M. Chromosomal aberrations of cancer-testis antigens in myeloma patients. Hematol Oncol 2014; 33:159-63. [PMID: 24820892 DOI: 10.1002/hon.2143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 03/10/2014] [Accepted: 03/12/2014] [Indexed: 12/26/2022]
Abstract
Cancer-testis antigens (CTAgs) play a major role in the immune response against cancer, but their biological functions in germ and cancer cells is still unclear. MAGE-C1 and MAGE-C2 are two CTAgs located at the Xq27 region of chromosome X and frequently expressed in multiple myeloma. Chromosomal rearrangements often occur in myeloma. We therefore investigated whether numerical and structural chromosomal aberrations correlate with their protein expression in primary multiple myelomas. To this aim, we designed new fluorescence in situ hybridization probes specific for the MAGE region in the Xq27 region and evaluated simultaneously aberrations of the X chromosome centromere. The comparison of MAGE copy number and chromosome X status revealed that MAGE copy number changes occurred in 6/43 (14%) cases, independent of concomitant X chromosome alterations. These numerical aberrations are less frequent than the expression of MAGE-C1 and MAGE-C2 (63% and 27% of patients, respectively) and do not always correlate with MAGE-C1 and MAGE-C2 expressions, suggesting alternative regulatory mechanisms in the expression of these genes.
Collapse
Affiliation(s)
| | | | - Alexander Vogetseder
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Alexander Knuth
- Departement of Oncology, University Hospital Zurich, Zurich, Switzerland
| | - Holger Moch
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Davide Soldini
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Marianne Tinguely
- Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.,Kempf and Pfaltz, Histologische Diagnostik, Zurich, Switzerland
| |
Collapse
|
50
|
Feuvret L, Vinchon S, Martin V, Lamproglou I, Halley A, Calugaru V, Chea M, Valéry CA, Simon JM, Mazeron JJ. Stereotactic radiotherapy for large solitary brain metastases. Cancer Radiother 2014; 18:97-106. [PMID: 24439342 DOI: 10.1016/j.canrad.2013.12.003] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Revised: 12/02/2013] [Accepted: 12/04/2013] [Indexed: 10/25/2022]
Abstract
PURPOSE To assess effectiveness and toxicity levels of stereotactic radiation therapy without whole brain radiation therapy in patients with solitary brain metastases larger than 3cm. PATIENTS AND METHODS Between June 2007 and March 2009, 12 patients received fractionated stereotactic radiation therapy and 24 patients underwent stereotactic radiosurgery. For the fractionated stereotactic radiation therapy group, 3×7.7Gy were delivered to the planning target volume (PTV); median volume and diameter were 29.4 cm(3) and 4.4cm, respectively. For the stereotactic radiosurgery group, 14Gy were delivered to the PTV; median volume and diameter were 15.6 cm(3) and 3.7cm, respectively. RESULTS Median follow-up was 218 days. For the fractionated stereotactic radiation therapy group, local control rates were 100% at 360 days and 64% at 720 days; for the stereotactic radiosurgery group, rates were 58% at 360 days and 48% at 720 days (P=0.06). Median survival time was 504 days for the fractionated stereotactic radiation therapy group and 164 days for the stereotactic radiosurgery group (P=0.049). Two cases of grade 2 toxicity were observed in the fractionated stereotactic radiation therapy group, and 6 cases of grade 1-2 toxicity, in the stereotactic radiosurgery group. CONCLUSIONS This study provides data to support that fractionated stereotactic radiation therapy without whole brain radiation therapy with a margin dose of 3 fractions of 7.7Gy for treatment of solitary large brain metastases is efficient and well-tolerated. Because of the significant improvement in overall survival, this schedule should be assessed in a randomized trial.
Collapse
Affiliation(s)
- L Feuvret
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
| | - S Vinchon
- Centre Paul-Papin, 2, rue Moll, 49100 Angers cedex, France
| | - V Martin
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - I Lamproglou
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - A Halley
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - V Calugaru
- Centre de protonthérapie d'Orsay (CPO), institut Curie, bâtiment 101, campus universitaire, 91898 Orsay cedex, France
| | - M Chea
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - C A Valéry
- Unité de Gamma-Knife, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - J-M Simon
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - J-J Mazeron
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| |
Collapse
|